Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $137

Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $130 to $137.